BIIB
US EQUITY
Health Care
Biotechnology
CIK: 875045
Biogen (BIIB) Quant Factor Diagnostic & Fair Value Model
Biogen (Ticker: BIIB) is listed in the Health Care sector (Biotechnology). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$250.69
-1.24%
Latest Close (2026-10-23)
Market Cap: $37.04B
P/E Ratio: 29.1
Momentum Strength
3M / 12M
+25.26%
1M: +10.75%
12M: +69.71%
Quality (ROE)
Point-in-Time
+6.85%
Trailing Return on Equity
Technical Trend
RSI 14
74.9
SMA50: $223.38
SMA200: $199.45
Valuation Multiplier
Trailing
29.1
Moderate Valuation Corridor (15x - 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Moderate Valuation Corridor (15x - 30x P/E)
BIIB trades within a typical sector multiple band (29.1x P/E), broadly aligned with trailing earnings.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 8/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 875045 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-03-31 | 2026-04-29 | $2.48B | $319.50M | $645.50M | $2.15 |
| 10-Q | 2025-12-31 | 2026-04-29 | - | - | - | - |
| 10-Q | 2025-03-31 | 2026-04-29 | $2.43B | $240.50M | $259.30M | $1.64 |
| 10-K | 2025-12-31 | 2026-02-06 | $9.89B | $1.29B | $2.20B | $8.79 |
| 10-K | 2024-12-31 | 2026-02-06 | $9.68B | $1.63B | $2.88B | $11.18 |
| 10-K | 2023-12-31 | 2026-02-06 | $9.84B | $1.16B | $1.55B | $7.97 |
| 10-Q | 2025-09-30 | 2025-10-30 | $2.53B | $466.50M | $1.69B | $3.17 |
| 10-Q | 2024-12-31 | 2025-10-30 | - | - | - | - |
💡 Methodology & Frequently Asked Questions
Key reference details regarding Biogen (BIIB) valuation multiples, momentum factors, and point-in-time filing conventions.
How should BIIB's current valuation multiple be interpreted? ↓
BIIB trades at a trailing P/E of 29.1x within the Health Care sector (moderate valuation corridor (15x - 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are BIIB's key momentum and technical factor indicators? ↓
As of the latest close, BIIB shows a 1-month return of +10.75%, 3-month return of +25.26%, and 12-month return of +69.71%, with a 14-day RSI of 74.9. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for BIIB? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can BIIB be incorporated into systematic factor models? ↓
BIIB can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.